Your browser doesn't support javascript.
Harmonization of Multiple SARS-CoV-2 Reference Materials Using the WHO IS (NIBSC 20/136): Results and Implications.
Windsor, William Jonathan; Roell, Yannik; Tucker, Heidi; Cheng, Chi-An; Suliman, Sara; Peek, Laura J; Pestano, Gary A; Lee, William T; Zeichhardt, Heinz; Lamb, Molly M; Kammel, Martin; Wang, Hui; Kedl, Ross; Rester, Cody; Morrison, Thomas E; Davenport, Bennet J; Carson, Kyle; Yates, Jennifer; Howard, Kelly; Kulas, Karen; Walt, David R; Dafni, Aner; Taylor, Daniel; Chu, May.
  • Windsor WJ; Colorado School of Public Health, Center for Global Health, Aurora, CO, United States.
  • Roell Y; Colorado School of Public Health, Center for Global Health, Aurora, CO, United States.
  • Tucker H; Division of Infectious Diseases, New York State Department of Health, Wadsworth Center, Albany, NY, United States.
  • Cheng CA; Department of Pathology, Brigham and Women's Hospital, Boston, MA, United States.
  • Suliman S; Division of Rheumatology, Inflammation and Immunity, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, United States.
  • Peek LJ; Division of Experimental Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, CA, United States.
  • Pestano GA; Biodesix, Inc., Boulder, CO, United States.
  • Lee WT; Biodesix, Inc., Boulder, CO, United States.
  • Zeichhardt H; Division of Infectious Diseases, New York State Department of Health, Wadsworth Center, Albany, NY, United States.
  • Lamb MM; INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories, Duesseldorf, Germany.
  • Kammel M; IQVD GmbH, Institut fuer Qualitaetssicherung in der Virusdiagnostik, Berlin, Germany.
  • Wang H; GBD Gesellschaft fuer Biotechnologische Diagnostik mbH, Berlin, Germany.
  • Kedl R; Colorado School of Public Health, Center for Global Health, Aurora, CO, United States.
  • Rester C; INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories, Duesseldorf, Germany.
  • Morrison TE; IQVD GmbH, Institut fuer Qualitaetssicherung in der Virusdiagnostik, Berlin, Germany.
  • Davenport BJ; GBD Gesellschaft fuer Biotechnologische Diagnostik mbH, Berlin, Germany.
  • Carson K; Thermo Fisher Scientific, Waltham, MA, United States.
  • Yates J; Department of Immunology, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
  • Howard K; Department of Immunology, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
  • Kulas K; Department of Immunology, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
  • Walt DR; Department of Immunology, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
  • Dafni A; Division of Infectious Diseases, New York State Department of Health, Wadsworth Center, Albany, NY, United States.
  • Taylor D; Division of Infectious Diseases, New York State Department of Health, Wadsworth Center, Albany, NY, United States.
  • Chu M; Division of Infectious Diseases, New York State Department of Health, Wadsworth Center, Albany, NY, United States.
Front Microbiol ; 13: 893801, 2022.
Article in English | MEDLINE | ID: covidwho-1903084
ABSTRACT

Background:

There is an urgent need for harmonization between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serology platforms and assays prior to defining appropriate correlates of protection and as well inform the development of new rapid diagnostic tests that can be used for serosurveillance as new variants of concern (VOC) emerge. We compared multiple SARS-CoV-2 serology reference materials to the WHO International Standard (WHO IS) to determine their utility as secondary standards, using an international network of laboratories with high-throughput quantitative serology assays. This enabled the comparison of quantitative results between multiple serology platforms.

Methods:

Between April and December 2020, 13 well-characterized and validated SARS-CoV-2 serology reference materials were recruited from six different providers to qualify as secondary standards to the WHO IS. All the samples were tested in parallel with the National Institute for Biological Standards and Control (NIBSC) 20/136 and parallel-line assays were used to calculate the relevant potency and binding antibody units.

Results:

All the samples saw varying levels of concordance between diagnostic methods at specific antigen-antibody combinations. Seven of the 12 candidate materials had high concordance for the spike-immunoglobulin G (IgG) analyte [percent coefficient of variation (%CV) between 5 and 44%].

Conclusion:

Despite some concordance between laboratories, qualification of secondary materials to the WHO IS using arbitrary international units or binding antibody units per milliliter (BAU/ml) does not provide any benefit to the reference materials overall, due to the lack of consistent agreeable international unit (IU) or BAU/ml conversions between laboratories. Secondary standards should be qualified to well-characterized reference materials, such as the WHO IS, using serology assays that are similar to the ones used for the original characterization of the WHO IS.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Diagnostic study / Prognostic study Topics: Variants Language: English Journal: Front Microbiol Year: 2022 Document Type: Article Affiliation country: Fmicb.2022.893801

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Diagnostic study / Prognostic study Topics: Variants Language: English Journal: Front Microbiol Year: 2022 Document Type: Article Affiliation country: Fmicb.2022.893801